Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors
|
|
|
- Theodore Clarke
- 10 years ago
- Views:
Transcription
1 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Beghetti Maurice Galie Nazzareno - Novartis : Pulmonary hypertension imatinib (2012) - Pfizer : Pulmonary hypertension sildenafil ( ) - Bayer Schering Pharma : Pulmonary hypertension riociguat ( ) - Eli Lilly : Pulmonary hypertension tadalafil ( ) - Actelion : Pulmonary hypertension, Tracleer, Macitentan, Selexipag ( ) - GlaxoSmithKline : pulmonary hypertension Ambrisentan ( ) - Novartis : Pulmonary hypertension riociguat (2013) - GlaxoSmithKline : ambrisentan (2014) - Actelion : no relation to a specific product ( ) - Bayer Schering Pharma : no relation to a specific product ( ) - Eli Lilly : pulmonary hypertension ( ) - Novartis : pulmonary hypertension ( ) - Pfizer : pulmonary hypertension ( ) - Actelion : pulmonary hypertension ( ) - GlaxoSmithKline : pulmonary hypertension ( ) - Bayer AG : pulmonary hypertension ( ) - GSK : Ambrisentan and Tadalafil (2014) - Actelion : macitentan (2014) - Bayer Healthcare : Riociguat ( ) - Pfizer : sildenafil ( ) - GSK : Ambrisentan, Tadalafil, epoprostenol (2015) 1/48
2 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Galie Nazzareno - Actelion : macitentan, bosentan, epoprostenol, selexipag (2015) - Pfizer : pulmonary hypertension ( ) - Actelion : pulmonary hypertension ( ) - GlaxoSmithKline : pulmonary hypertension ( ) - Bayer AG : pulmonary hypertension ( ) - GSK : ambrisentan and Tadalafil ( ) - Bayer Healthcare : riociguat ( ) - Actelion : Selexipag ( ) - Pfizer : sildenafil ( ) Ghofrani Hossein Ardeschir - Novartis : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - Bayer Healthcare : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) - Ergonex : Pulmonary Hypertension (2013) - Gilead : Pulmonary Hypertension ( ) - Merck Sharp & Dohme : Pulmonary Hypertension ( ) - Bellerophon : Pulmonary hypertension (2015) - Pfizer : Pulmonary Hypertension and other lung diseases (2012) - Actelion : Pulmonary Hypertension ( ) 2/48
3 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Ghofrani Hossein Ardeschir - Bayer Healthcare : Pulmonary Hypertension ( ) - Ergonex : Pulmonary Hypertension (2013) - Pfizer : Pulmonary Hypertension ( ) Gibbs Simon - GlaxoSmithKline : Pulmonary hypertension: ambrisentan, Flolan (2012) - Actelion : Pulmonary hypertension: bosentan, macitentan (2012) - Lilly : Pulmonary hypertension: Tadalafil (2012) - United Therapeutics : Pulmonary hypertension: Treprostinil (2012) - Novartis : Trial adjudication Committee member ( ) - Bayer AG : Pulmonary hypertension: riociguat ( ) - Pfizer : Pulmonary hypertension: Sildenafil ( ) - Gilead : Trial Adjudication Committee member ( ) - AOP Orphan Pharmaceuticals : Pulmonary hypertension (2013) - Actelion : Pulmonary hypertension: bosentan, macitentan; Trial adjudication Committee member (2013) - GlaxoSmithKline : Pulmonary hypertension: ambrisentan, epoprostenol ( ) - Actelion : Pulmonary hypertension: bosentan, macitentan; epoprostenol ( ) Gomez Sanchez Miguel Angel - United Therapeutics : Pulmonary hypertension: treprostinil (2012) - GlaxoSmithKline : ambrisentan, tadalafil (2012) - Servier : ivabradine ( ) - Actelion : macitentan ( ) - Bayer Schering Pharma : riociguat ( ) - Ferrer Internacional : treprostinil ( ) 3/48
4 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Hansmann Georg Nothing to be declared ( ) Hoeper Marius M - Novartis : Imatinib (2012) - Lilly : Tadalafil (2012) - GlaxoSmithKline : Ambrisentan ( ) - Actelion : Bosentan, Macitentan ( ) - Bayer AG : Iloprost, Riociguat ( ) - Pfizer : Sildenafil ( ) Humbert Marc - Lilly : Pulmonary Hypertension ( ) - Aires : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension ( ) - Novartis : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) Klepetko Walter Nothing to be declared ( ) Lancellotti Patrizio - Boston Scientific : Heart Failure (2012) 4/48
5 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Lancellotti Patrizio - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012) - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) Lang Irene Marthe - Actelion : Pulmonary Hypertension (2013) - Actelion : Bosentan ( ) - Cordis : Cypher ( ) - Astra Zeneca : Rosiglitazone ( ) - Lilly : Tadalafil, ReoPro ( ) - Merck Sharp & Dohme : Vernakalant ( ) - GlaxoSmithKline : Ambrisentan ( ) - Boehringer-Ingelheim : Dabigatran ( ) - Spectranetics : Laser ( ) - Servier : Procoralan ( ) 5/48
6 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Lang Irene Marthe - Medtronic : Resolute ( ) - Bayer Healthcare : Riociguat ( ) - Boston Scientific : stents ( ) - Biotronik : stents ( ) - United Therapeutics : Treprostinil ( ) - Actelion : Opsumit ( ) - Daiichi Sankyo : Prasugrel ( ) - Astra Zeneca : Rosuvastatin ( ) - Servier : Clarify Registry ( ) - Bayer Healthcare : CTEPH Academy Vienna (2015) - Actelion : Bosentan ( ) - Bayer : research funding ( ) Matucci-Cerinic Marco Nothing to be declared ( ) McDonagh Theresa Peacock Andrew - AbbVie, actelion, gsk, pfizer, bms : rheumatology (2015) - Vifor International : Ferrinject ( ) - Novartis : Honoraria ( ) - Servier : Ivabridine (2012) - Novartis : Heart Failure (2013) - Bayer : pulmonary hypertension ( ) 6/48
7 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Peacock Andrew - Actelion : pulmonary hypertension ( ) - GlaxoSmithKline : pulmonary hypertension ( ) - United Therapeutics : pulmonary hypertension ( ) Pierard Luc - Bayer : pulmonary hypertension ( ) - Siemens Healthcare : Echo machine (2012) - GE Healthcare : Echo machine VIVID (2012) - Bayer Healthcare : Rivaroxaban (2012) - Astra Zeneca : Rosuvastatine, Ticagrelor (2012) - Novartis : Aliskirene (2013) - Astra Zeneca : Rosuvastatin ( ) - Boehringer-Ingelheim : Dabigatran ( ) - Abbott Vascular : MitraClip ( ) - Bristol Myers Squibb : Apixaban (2015) - Boehringer-Ingelheim : Dabigatran (2015) - Abbott : MitraClip (2015) Simonneau Gerald - Astra Zeneca : Rosuvastatine ( ) - Eli Lilly : tadalafil (2012) - Bayer : Iloprost, riociguat ( ) - Pfizer : revatio ( ) - GlaxoSmithKline : ambrisentan ( ) 7/48
8 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Simonneau Gerald - Actelion : bosentan ( ) - Bayer Healthcare : Riociguat ( ) - Actelion : bosentan ( ) - Bayer Healthcare : riociguat ( ) E - Research funding (personal). - GlaxoSmithKline : ambris"entan ( ) - Actelion : bosentan ( ) - Bayer : iloprost, riociguat ( ) Torbicki Adam - Cardiomems : implanted pulmonary artery pressure sensor (2012) - United Therapeutics : Pulmonary arterial hypertension (2012) - Lilly : pulmonary arterial hypertension - tadalafil (2012) - AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012) - Bristol Myers Squibb : thromboembolic disease - Apixaban (2012) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan ( ) - Actelion : pulmonary arterial hypertension - macitentan, selexipag ( ) - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto ( ) - Bristol Myers Squibb : Pulmonary arterial hypertension ( ) - Lilly : pulmonary arterial hypertension - ambrisentan ( ) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015) - Sanofi Aventis : Thromboembolic disease (2012) - Bayer Healthcare : Pulmonary hypertension ( ) 8/48
9 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Trigo Trindade Pedro Nothing to be declared ( ) Vachiery Jean-Luc - Pfizer : Pulmonary Hypertension (sildenafil) (2012) - Eli Lilly : Pulmonary Hypertension (tadalafil) ( ) - GlaxoSmithKline : Pulmonary Hypertension (ambrisentan, epoprostenol) ( ) - Actelion : Pulmonary Hypertension (macitentan, bosentan) ( ) - Bayer Schering Pharma : Pulmonary Hypertension (riociguat, ventavis) ( ) - United Therapeutics : Pulmonary Hypertension (treprostinil) ( ) - Merck Sharp & Dohme : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension (ambrisentan) (2015) - Bayer Schering Pharma : Pulmonary hypertension (riociguat) (2015) - Actelion : Pulmonary Hypertension (selexipag, macitentan) (2015) - United Therapeutics : Pulmonary hypertension (treprostinill) (2015) Vonk Noordegraaf Antonie - Actelion : Pulmonary Hypertension (selexipag, macitentan) (2015) - Bayer Schering Pharma : ricociguat ( ) - Lilly : tardanafil ( ) - United Therapeutics : remodulin ( ) - Pfizer : Revatio ( ) - Actelion : tracleer ( ) - GlaxoSmithKline : Volibris ( ) - Bayer Schering Pharma : riociguat (2015) 9/48
10 Guidelines on Pulmonary Hypertension 2015 (TF08) - Task Force Members and Additional Contributors Zompatori Maurizio Nothing to be declared ( ) 10/48
11 Aboyans Victor Nothing to be declared (2013) - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension ( ) - Bayer Healthcare : Oral anticoagulation ( ) - Merck Sharp & Dohme : Antithrombotics (2015) Achenbach Stephan - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) - Abbott : Coronary Intervention ( ) - Siemens Healthcare : Imaging ( ) Agewall Stefan - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013) 11/48
12 Agewall Stefan - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition ( ) - Thermo Fischer Scientific : Cardiac markers ( ) Allanore Yannick - BMS : scleroderma (2013) - Biogen : scleroderma (2013) - Actelion : scleroderma ( ) - Sanofi Aventis : scleroderma ( ) - Bayer AG : scleroderma ( ) - Genentech / Roche : scleroderma ( ) - Medac : scleroderma ( ) - Inventiva : scleroderma ( ) - Pfizer : scleroderma, rheumatoid arthritis ( ) - UCB : rheumatoid arthritis ( ) - Actelion : bosentan, macitentan (2015) - Inventiva : fibrosis (2015) - cellgen : fibrosis (2015) - Servier : immunology (2015) - Roche Pharma : immunology (2015) - Pfizer : rheumatoid arthritis (2015) - Bayer Healthcare : riociguat (2015) 12/48
13 Allanore Yannick - Sanofi/Genzyme : scleroderma ( ) - Inventiva : fibrosis (2015) - Pfizer : immunology (2015) - BMS : immunology (2015) E - Research funding (personal). - Servier : scleroderma (2013) - Genentech / Roche : scleroderma (2013) - Inventiva : scleroderma ( ) Andreassen Arne Kristian - United Therapeutics : Remodulin / Pulmonary arterial hypertension ( ) - Actelion : PAH specific drugs ( ) - GlaxoSmithKline : PAH specific drugs ( ) - Bayer : Riociguat ( ) Anton Ly Asteggiano Riccardo Badano Luigi Paolo - Quintiles : Investigator in Phase III Trial to evaluate the efficacy of Ularitide in patients with acute heart failure ( ) - Bayer : Seminar of pulmonary hypertension (2015) - GlaxoSmithKline : Prospective cross-sectional and long-term longitudinal epdemiological study on pulmonary arterial hypertension (PAH) in Estonia ( ) - Chiesi Pharma : Rosuvastatin ( ) - Edwards Lifesciences : Prosthetic valves (2015) - SamsungMedison : Ultrasound (2013) - Edwards Lifesciences : Clinical Event Comittee member ( ) 13/48
14 Badano Luigi Paolo - Sorin Group : Consultancy ( ) - GE Healthcare : Ultrasound ( ) - Edwards Lifesciences : Heart valve prostheses. Clinical Event Comittee member (2015) - Sorin Group : Heart valve prostheses. Consultancy (2015) - Epygon : Start-up, bioprostheses. Advisory board (2015) Barbera Joan Albert - Epygon : Heart valve prostheses (2015) - GE Healthcare : Ultrasound ( ) E - Research funding (personal). - GE Healthcare : Ultrasound (2013) - Almirall Spain : Chronic Obstructive Pulmonary Disease ( ) - Bayer : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - Ferrer Internacional : Pulmonary Hypertension (2015) Bauer Fabrice - Medtronic : cardiac resynchronisation ( ) - Actelion : pulmonary hypertension ( ) 14/48
15 Bauer Fabrice - Daiichi Sankyo : systemic hypertension ( ) - Bayer : Pulmonary Hypertension vasodilatation therapy (2015) - Actelion : Pulmonary Hypertension vasodilatation therapy (2015) - GSK : Pulmonary Hypertension vasodilatation therapy (2015) - Bayer Healthcare : pulmonary hypertension ( ) - GSK : pulmonary hypertension (2014) Bondermann Diana Botnaru Victor Bouvaist Helene - Actelion, United Therapeutics, AOP, Novartis, Pfizer, Bayer Healthcare : Pulmonary hypertension, left heart failure (2013) - Actelion, Bayer Lifesciences, AOP, Pfizer, GSK : pulmonary hypertension, left heart failure ( ) E - Research funding (personal). - Bayer Healthcare : Pulmonary hypertension, left heart failure (2013) - GlaxoSmithKline : asthma treatment (2013) - Berlinchemie : allergy treatment ( ) - Actelion for speaker fees : PAH medication ( ) - Bayer for speaker fees : CTEPH medication (2015) - Actelion for speaker fees : PAH medication (2015) - GSK for speaker fees : PAH medication (2015) Bueno Hector - Biosensors : stent ( ) - BMS/Pfizer : Apixaban (2013) - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) 15/48
16 Bueno Hector - Bayer Healthcare : Aspirin, rivaroxaban ( ) - Sanofi Aventis : Clopidogrel ( ) - Daiichi Sankyo : Prasugrel ( ) - Eli Lilly : Prasugrel ( ) - Astra Zeneca : Ticagrelor ( ) - Novartis : Serelaxin (2014) - Pfizer : Apixaban ( ) - Bristol Myers Squibb : Apixaban ( ) - Servier : ivabradine ( ) - Menarini : Ranolazine ( ) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) E - Research funding (personal). - Astra Zeneca : Ticagrelor ( ) Byrne Robert Nothing to be declared (2013) - Boston Scientific : Medical devices ( ) - Biotronik : Medical devices ( ) - B.Braun : Medical devices ( ) Carerj Scipione Nothing to be declared ( ) 16/48
17 Castro Maria Da Graca - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) - Bayer Schering Pharma : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) Chukhrukidze Archil Nothing to be declared ( ) - Bayer Schering Pharma : Pulmonary Hypertension ( ) Cikes Maja - Astellas : Heart transplantation (2013) - Pfizer : Hypertension (2013) - Berlin Chemie AG : Hypertension (2013) - Sanofi Aventis : Hypertension, ACS (2013) - Roche Diagnostics : Heart failure biomarkers (2014) - Novartis : Heart transplant (2014) - Berlin Chemie AG : Ischaemic heart disease (2014) - Bayer : Anticoagulation ( ) - GE Healthcare : Cardiac Ultrasound (2015) - Novartis : Heart Failure (2015) Coghlan John G - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) 17/48
18 Coghlan John G - Endotronix : Endovascular pressure monitoring systems ( ) - Bayer : Pulmonary Hypertension (2015) Coman Ioan Mircea C - Receipt of royalties for intellectual property. - Springer : Medical Education ( ) - Actelion : Pulmonary Hypertension ( ) - Lung Rx : PHT (2013) - Daiichi Sankyo : anticoagulants ( ) - Sanofi Aventis : dyslipidemia ( ) - Amgen Inc : dyslipidemia ( ) - Fournier Laboratories : dyslipidemia ( ) - Novartis : HF ( ) - Lung Rx : PHT (2013) - Daiichi Sankyo : anticoagulants ( ) - Sanofi Aventis : dyslipidemia ( ) - Amgen Inc : dyslipidemia ( ) - Fournier Laboratories : dyslipidemia ( ) - Novartis : HF ( ) - Geneva Romfarm : Pht (2015) De Pauw Michel - Actelion : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension ( ) 18/48
19 De Pauw Michel - Pfizer : Pulmonary Hypertension ( ) Emdin Michele Nothing to be declared ( ) Erol Cetin Falk Volkmar - Servier : Hypertension ( ) - Menarini : Hypertension ( ) - Boston Scientific : Valves (2013) - Edwards Lifesciences : Valves (2013) - Medtronic : valves (2013) - Valtech : Valves (2013) - Berlin Heals : cell modification ( ) - Boston Scientific : heart valves ( ) - Edwards Lifesciences : heart valves ( ) - Medtronic : heart valves ( ) - Aesculap : minimally invasive mitral surgery ( ) - Philips : Imaging ( ) - Heartware : LVAD ( ) Funck-Brentano Christian - Lundbeck : Cardiac safety of an antidepressant (2013) - Actelion : Consulting on the potential developement of a calcium inhibitor (2013) - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products ( ) - Teva Pharmaceutical Industries : DSMB in an oncology phase IIb trial ( ) 19/48
20 Funck-Brentano Christian - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. ( ) - Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. ( ) - MMV (CH) : Cardiac Saftey of two antimalarial drugs ( ) - Ipsen : Cardiac saftey of a product for cleansing of the colon prior to bowel procedures (2014) - Intracellular Therapies USA : Cardiac Safety of non-cardiovasclar products ( ) - Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology ( ) - Bristol Myers Squibb USA : Review of pharmacovigilance cases for an antiviral drug (2015) Gaine Sean - Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2013) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) - Bayer AG : Pulmonary Hypertension ( ) - Actelion : GRIPHON Clinical Trial (Institution) ( ) - Pfizer : PH (Grant to Hospital): ( ) - GSK : PH/Asthma/COPD: Grant to Hospital ( ) - Bayer AG : Thrombosis and PH (Grant to Hospital) ( ) Giannakoulas George - Novartis : Acute Heart Failure ( ) - Astra Zeneca : Cardiovascular risk ( ) - Menarini : Chronic coronary artery disease ( ) - Bayer : Pulmonary Hypertension ( ) 20/48
21 Giannakoulas George - Actelion : Pulmonary Hypertension ( ) - Pfizer : Chronic Heart Failure, Atrial Fibrillation (2014) - Servier : Chronic coronary artery disease ( ) - MSD : Hyperlipidemia ( ) - Pfizer : Atrial Fibrillation (2015) - Astra Zeneca : Coronary artery disease (2015) - Bayer : Pulmonary Hypertension - Atrial Fibrillation (2015) Gorenflo Matthias Granton John - Actelion : Bosentan ( ) - Bayer Schering Pharma : Iloprost ( ) C - Receipt of royalties for intellectual property. - Pfizer : Sildenafil ( ) - Gore : ASD-Devices (2015) - Ikaria : inhaled Nitric oxide. Member of sterring committee ( ) - Actelion : Pulmonary Hypertension - member of DSMC ( ) - Bayer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - Lilly : Pulmonary Hypertension ( ) - Actelion : Pulmonary hypetension ( ) - Pfizer : Pulmonary Hypertension ( ) 21/48
22 Granton John - Bayer : Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension (2015) Gumbiene Lina Nothing to be declared ( ) Ibrahimov Firdovsi Nothing to be declared ( ) Iung Bernard - Bayer : rivaroxaban (2013) - Boehringer-Ingelheim : dabigatran ( ) - Edwards Lifesciences : heart valve prosthesis ( ) - Abbott : Mitraclip ( ) Jaaskelainen Pertti - Novartis : serelaxin/heart failure Advisory Board fee ( ) - Boehringer-Ingelheim : speaker fee ( ) - Astra Zeneca : ticagrelor Advisory Board fee; speaker fees ( ) - Roche Pharma : psychiatry ( ) - Shire HGT : psychiatry ( ) - Servier : psychiatry ( ) - Lundbeck : psychiatry (2015) E - Research funding (personal). - Kuopio University Hospital, Department of Medicine : temporary employment as a researcher in 2013 (2013) - Kuopio University Hospital, Department of Medicine : temporary employment as a researcher in 2014 (2014) Jansa Pavel - Actelion : Bosentan, Macitentan ( ) - AOP Orphan Pharmaceuticals : Remodulin ( ) - Bayer Healthcare : Riociguat ( ) - Actelion : Bosentan, Macitentan ( ) 22/48
23 Jansa Pavel - Bayer Healthcare : Riociguat ( ) Karlocai Kristof - Actelion : Bosentan, Macitentan ( ) - AOP Orphan Pharmaceuticals : Remodulin ( ) - Pfizer : Revatio ( ) - Actelion : Tracleer ( ) - GlaxoSmithKline : Volibris, Flolan ( ) - Lilly : Adcirca ( ) - Bayer Healthcare : Adempas ( ) - Actelion : Tracleer ( ) Kaymaz Cihangir Nothing to be declared ( ) Kiely David G - Bayer Healthcare (Only Institutional payment without any payment to me) : Pulmonary Hypertension, Advisory Board (2015) - Bayer : Pulmonary embolism and pulmonary hypertension (2013) - Actelion Pharmaceuticals : Pulmonary Hypertension (2013) - GSK : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension and Pulmonary Embolism ( ) - Bayer : Imaging and pulmonary hypertension (2013) - Actelion : Pulmonary Hypertension ( ) - Bayer : Pulmonary Hypertension ( ) 23/48
24 Kirchhof Paulus - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular ( ) - Daiichi Sankyo : cardiovascular ( ) - Medtronic : cardiovascular ( ) - Pfizer : cardiovascular ( ) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) - Bristol Myers Squibb : cardiovascular ( ) - Merck Sharp & Dohme : cardiovascular ( ) - Medscape : cardiovascular ( ) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015) - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) 24/48
25 Kirchhof Paulus - Daiichi Sankyo : cardiovascular ( ) - British Heart Foundation : cardiovascular ( ) - BMS / Pfizer alliance : cardiovascular ( ) - Leducq Foundation : cardiovascular ( ) - European Union FP7 : cardiovascular ( ) - European Union horizon2020 : cardiovascular ( ) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular ( ) Kjellstrom Barbro Nothing to be declared ( ) Kurzyna Marcin - Actelion : pulmonary hypertension ( ) - GlaxoSmithKline : pulmonary hypertension ( ) - AOP Orphan Pharmaceuticals : pulmonary hypertension ( ) - Bayer Healthcare : pulmonary hypertension, thrombosis ( ) - Pfizer : pumonary hypertension ( ) - Sanofi Aventis : thrombosis ( ) Landmesser Ulf - Sanofi Aventis : thrombosis ( ) - Roche Pharma : Cardiovascular Research (2013) - Amgen : Advisory Board, Speakers fee ( ) - Sanofi Aventis : Advisory Board, Speakers fee ( ) - MSD : Advisory Board, Speakers fee ( ) - Roche Pharma : Research grant, Advisory Board ( ) 25/48
26 Landmesser Ulf - Pfizer : Research grant, Speakers fee ( ) - St. Jude : Advisory Board (2015) Lazareva Irina - Servier : arterial hypertension (2013) - Actelion : macitentan (SERAPHIN OL) (2014) - Actelion : macitentan (SERAPHIN OL), selexipag (GRIPHON OL) (2015) - Actelion : pulmonary hypertension, sub-investigator in trials SERAPHIN, GRIPHON (2013) Lebrun Frederic Nothing to be declared (2015) - Actelion : macitentan (SERAPHIN OL) (2014) - Bayer Healthcare : Rivaroxaban ( ) - Boehringer-Ingelheim : Dabigatran (2014) Lekakis John - Pfizer : HEART FAILURE (2013) - Astra Zeneca : HYPERLIPIDEMIA (2013) - MSD : Inegy ( ) - Actelion : Macitentan ( ) - Menarini : RANOLAZINE ( ) - Bayer : RIVAROXABAN ( ) - Astra Zeneca : ROSUVASTATIN ( ) Lionis Christos - Amgen : Speaker fees (2013) - GlaxoSmithKline : Speaker fees (2013) - Pfizer Hellas : Speaker fees (2013) 26/48
27 Lionis Christos - Spring to Life Ltd : Teaching fees (2015) - Leo Pharma : consultancy fees (2014) - MSD : speaker fees (2014) - UCB : speaker fees (2014) - Vianex : speaker fees (2014) - APR : speaker fees (2014) - Pfizer International Operations : speaker fees (2014) - GlaxoSmithKline : teaching fees (2014) Lip Gregory Y H - Pfizer : Community acquired pneumonia epidemiological research study. No product or therapeutic area. (2013) - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation ( ) - Boehringer-Ingelheim : atrial fibrillation, thrombosis ( ) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) - Pfizer : atrial fibrillation, thrombosis ( ) - Bayer Healthcare : atrial fibrillation, thrombosis ( ) - Bristol Myers Squibb : atrial fibrillation, thrombosis ( ) - Medtronic : atrial fibrillation ( ) - Roche Diagnostics : anticoagulation (2015) - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) 27/48
28 Mahdhaoui Abdallah Nothing to be declared ( ) Menachemi Doron Nothing to be declared ( ) - Novartis : Heart Failure Treatment (2015) Micallef Josef Nothing to be declared ( ) Moiseeva Olga - Bayer Healthcare : pulmonary hypertension ( ) - Actelion : pulmonary hypertension (2015) - GlaxoSmithKline : pulmonary hypertension (2015) - Actelion : pulmonary hypertension ( ) - Bayer Healthcare : pulmonary hypertension ( ) - Servier : Heart Failure ( ) Moutiris Joseph Antoniou Nothing to be declared ( ) Myftiu Sokol Nothing to be declared ( ) Nielsen-Kudsk Jens Erik - St Jude Medical : Interventional Cardiology (consultant) ( ) - Bayer : Pulmonary Hypertension (advisory board) ( ) - Actelion : Pulmonary Hypertension (speeker fee) ( ) - GSK : Pulmonary Hypertension (speeker fee) (2015) - Gore : Interventional Cardiology (investigator) ( ) Oddsson Hjortur Nothing to be declared ( ) - Bayer : Pulmonary Hypertension (investigator) ( ) - Actelion : Pulmonary Hypertension (Investigator) ( ) 28/48
29 Opitz Christian - Bayer : Pulmonary Hypertension ( ) - Novartis : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) Orfanos Stylianos - Actelion : Pulmonary Hypertension ( ) - Actelion : pulmonary arterial hypertension ( ) - United Therapeutics : pulmonary arterial hypertension ( ) - Pharmaserve Lilly : pulmonary arterial hypertension ( ) - Bayer : pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension ( ) - Novagem : pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (2015) - Actelion : pulmonary arterial hypertension ( ) - Pfizer : pulmonary arterial hypertension (RCT & research) and pulmonary fibrosis (research) (2013) - Bayer : pulmonary arterial hypertension (RCT) ( ) - GlaxoSmithKline : pulmonary arterial hypertension (RCT) ( ) - United Therapeutics : pulmonary fibrosis (research) ( ) - Pfizer : pulmonary arterial hypertension (RCT) (2014) Oukerraj Latifa Nothing to be declared ( ) - United Therapeutics : pulmonary arterial hypertension (RCT) (2015) Park Myung H - Bayer : PAH medication ( ) 29/48
30 Park Myung H - United Therapeutics : PAH medication ( ) - Gilead : PAH medication ( ) - Actelion : PAH medications ( ) - Bayer : PAH Therapeutics (2015) - Actelion : PAH Therapeutics (2015) - United Therapeutics : PAH Therapeutics (2015) - Gilead : PAH Therapeutics (2015) - Bayer : PAH therapies ( ) - Actelion : PAH therapies ( ) - United Therapeutics : PAH therapies ( ) - Gilead : PAH therapies ( ) - Actelion : PAH Therapeutics (2015) Piepoli Massimo Francesco Nothing to be declared ( ) Ponikowski Piotr - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant ( ) - Respicardia : anticoagulant ( ) - Johnson & Johnson : heart failure ( ) - Pfizer : heart failure, anticoagulant ( ) - Abbott Vascular : devices ( ) 30/48
31 Ponikowski Piotr - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - Vifor Pharma ltd : heart failure ( ) - CIBIEM : heart failure ( ) - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome ( ) - Boehringer-Ingelheim : anticoagulant, diabetes (2015) - Respicardia : devices (2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2014) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome ( ) - Respicardia : anticoagulant ( ) - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - CIBIEM : heart failure ( ) 31/48
32 Ponikowski Piotr - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2013) - Singulex : biomarkers (2015) Revel Marie-Pierre Nothing to be declared ( ) Ribeiro Leite Baptista Maria Joao Nothing to be declared ( ) Rigau David Nothing to be declared ( ) Rosenkranz Stephan - Actelion : Pulmonary Hypertension ( ) - GlaxoSmithKline : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) - Pfizer : Pulmonary Hypertension, Anticoagulants ( ) - Novartis : Pulmonary Hypertension, Heart Failure ( ) - Bayer : Pulmonary Hypertension, Heart Failure, Anticoagulants ( ) - BMS : Anticoagulation ( ) - Bayer : Pulmonary Hypertension ( ) - Actelion : Pulmonary Hypertension ( ) - United Therapeutics : Pulmonary Hypertension ( ) 32/48
33 Rosenkranz Stephan - AOP Orphan Pharmaceuticals : Pulmonary Hypertension ( ) Rudzitis Ainars Nothing to be declared (2013) - Novartis : Pulmonary Hypertension, Heart Failure ( ) - Sequel Pharmaceutics : Arterial hypertension (2014) - Servier : Arterial Hypertension (2015) - Shire HGT : Pulmonary Hypertension (2015) Schwerzmann Markus - Actelion : Pulmonary hypertension ( ) - Bayer Healthcare : Pulmonary hypertension (2014) - Actelion : Pulmonary hypertension ( ) - Bayer Healthcare : Pulmonary hypertension (2015) Simkova Iveta - GlaxoSmithKline : ambrisentan (2013) - Pfizer : eplerenon, sildenafil, apixaban (2013) - Bayer : rivaroxaban ( ) - AOP Orphan Pharmaceuticals : treprostinil ( ) - Servier : arterial hypertension ( ) - Merck Serono : bisoprolol ( ) - Actelion : bosentan ( ) - Pfizer : apixaban (2014) - Bayer : riociguat (2015) Sirenko Yuriy - Takeda Pharmaceuticals : Azilsartan ( ) 33/48
34 Sirenko Yuriy - Pfizer : Cardiovascular (2015) - Servier : Cardiovascular (2015) - Sanofi Aventis : Cardiovascular (2015) - Menarini : Cardiovascular (2015) - Takeda Pharmaceuticals : Cardiovascular (2015) - Servier : perindopril+amlodipine+indapamide ( ) - Pfizer : amlodipine + atorvastatin (2014) Sokolovic Sekib Nothing to be declared ( ) Sooronbaev Talant Nothing to be declared ( ) Srbinovska-Kostovska Elizabeta Nothing to be declared ( ) Stefanovic Branislav Nothing to be declared ( ) van Dijk Arie - Servier : Prexanor (2014) - Actelion : Pulmonary arterial hypertension treatment ( ) - Pfizer : PAH treatment ( ) - Actelion : PAH-treatment ( ) Vaz Carneiro Antonio Nothing to be declared (2015) Velchev Vasil - AbbVie : Oncology ( ) - Boston Scientific : Inetrventional cardiology ( ) - Astra Zeneca : Ticagrelor, Crestor ( ) 34/48
35 Velchev Vasil - Servier : Trimetazidine, Ivabradine ( ) Voller Heinz Nothing to be declared ( ) Wikstrom Bernt Gerhard - The German pension insurance : Government of technician and science (2013) - Novartis : Heart failure (2013) - Servier : Heart Failure (2013) - Actelion : PAH (2013) - Bayer AG : Pulmonary Hypertension (2013) - GSK : pulmonary hypertension (2013) - Pfizer : cardiac amyloidosis ( ) - Novartis : Heart failure ( ) - Actelion : PAH ( ) - GSK : PAH ( ) - GE Healthcare : Heart failure (2015) - Servier Pharmaceutics : Heart Failure (2015) - Bayer Healthcare : PAH, CTEPH (2015) Zamorano Gomez Jose Luis - Uppsala University : PAH (2013) - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) 35/48
36 Zamorano Gomez Jose Luis - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors ( ) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo ( ) - Toshiba medical imaging : Fusion Imaging (2015) C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2013) - Amgen : Clinical trial ( ) - Novartis : Clinical trial ( ) - Ikaria : Clinical trial ( ) 36/48
37 Committee for Practice Guidelines MEMBERS Aboyans Victor Nothing to be declared (2013) - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension ( ) - Bayer Healthcare : Oral anticoagulation ( ) - Merck Sharp & Dohme : Antithrombotics (2015) Achenbach Stephan - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) - Abbott : Coronary Intervention ( ) - Siemens Healthcare : Imaging ( ) Agewall Stefan - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013) 37/48
38 Committee for Practice Guidelines MEMBERS Agewall Stefan - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition ( ) - Thermo Fischer Scientific : Cardiac markers ( ) Badimon Lina - Astra Zeneca : cardiovascular (2013) - Sanofi Aventis : cardiovascular (2013) - MSD-España : Lipids (2014) - Sanofi Aventis : lipids ( ) - Burson Masteller : nutrition ( ) - Astra Zeneca : thrombosis ( ) Baron Esquivias Gonzalo - Astrazeneca : thrombosis ( ) - Bayer : Anticoagulation ( ) - Boehringer-Ingelheim : Anticoagulation ( ) - Daiichi Sankyo : Anticoagulation ( ) - Pfizer : Anticoagulation ( ) - Menarini : Ischemic disease (2015) - Laboratorios Rovi : Ivabradine (2015) - Biotronik : Vasovagal syncope & Pacing (2013) - Bayer : Anticoagulation (2015) 38/48
39 Committee for Practice Guidelines MEMBERS Baumgartner Helmut - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease ( ) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Actelion : Bosentan for PAH treatment in congenital heart disease ( ) Bax Jeroen Nothing to be declared ( ) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Servier : Farma (2013) - Edwards Lifesciences : Heart Valves (2013) - GE Healthcare : Imaging (2013) - Lantheus Inc : Imaging (2013) - Boston Scientific : Pacing (2013) - Medtronic : Pacing (2013) - St Jude Medical : Pacing (2013) - Biotronik : Pacing (2013) Bueno Hector - BMS/Pfizer : Apixaban (2013) 39/48
40 Committee for Practice Guidelines MEMBERS Bueno Hector - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban ( ) - Sanofi Aventis : Clopidogrel ( ) - Daiichi Sankyo : Prasugrel ( ) - Eli Lilly : Prasugrel ( ) - Astra Zeneca : Ticagrelor ( ) - Novartis : Serelaxin (2014) - Pfizer : Apixaban ( ) - Bristol Myers Squibb : Apixaban ( ) - Servier : ivabradine ( ) - Menarini : Ranolazine ( ) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) E - Research funding (personal). - Astra Zeneca : Ticagrelor ( ) Carerj Scipione Nothing to be declared ( ) Erol Cetin - Servier : Hypertension ( ) - Menarini : Hypertension ( ) 40/48
41 Committee for Practice Guidelines MEMBERS Fitzsimons Donna Nothing to be declared ( ) - Amgen : FH Tratment options (2014) Gaemperli Oliver Nothing to be declared (2013) - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015) Kirchhof Paulus - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular ( ) - Daiichi Sankyo : cardiovascular ( ) - Medtronic : cardiovascular ( ) - Pfizer : cardiovascular ( ) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) - Bristol Myers Squibb : cardiovascular ( ) - Merck Sharp & Dohme : cardiovascular ( ) - Medscape : cardiovascular ( ) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015) 41/48
42 Committee for Practice Guidelines MEMBERS Kirchhof Paulus - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) - Daiichi Sankyo : cardiovascular ( ) - British Heart Foundation : cardiovascular ( ) - BMS / Pfizer alliance : cardiovascular ( ) - Leducq Foundation : cardiovascular ( ) - European Union FP7 : cardiovascular ( ) - European Union horizon2020 : cardiovascular ( ) Kolh Philippe H 2015) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular ( B.Braun : Surgical instruments ( ) - Astra Zeneca : Antiplatelet agents ( ) - St Jude Medical : Cardiac valves (2013) - Boston Scientific : Coronary stents (2013) - Siemens Healthcare : Medical imaging (2013) - Johnson & Johnson : Thoracoscopic devices (2013) 42/48
43 Committee for Practice Guidelines MEMBERS Kolh Philippe H - Edwards Lifesciences : Cardiac valves ( ) - Medtronic : Cardiac valves ( ) Lancellotti Patrizio - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) Lip Gregory Y H - Actelion : Pulmonary Hypertension (2013) - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation ( ) - Boehringer-Ingelheim : atrial fibrillation, thrombosis ( ) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) - Pfizer : atrial fibrillation, thrombosis ( ) - Bayer Healthcare : atrial fibrillation, thrombosis ( ) - Bristol Myers Squibb : atrial fibrillation, thrombosis ( ) - Medtronic : atrial fibrillation ( ) - Roche Diagnostics : anticoagulation (2015) 43/48
44 Committee for Practice Guidelines MEMBERS Lip Gregory Y H - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) Nihoyannopoulos Petros Nothing to be declared ( ) - GSK : Consultant for Imaging studies (2013) Piepoli Massimo Francesco Nothing to be declared ( ) Ponikowski Piotr - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant ( ) - Respicardia : anticoagulant ( ) - Johnson & Johnson : heart failure ( ) - Pfizer : heart failure, anticoagulant ( ) - Abbott Vascular : devices ( ) - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - Vifor Pharma ltd : heart failure ( ) - CIBIEM : heart failure ( ) - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - MSD : lipids (2014) 44/48
45 Committee for Practice Guidelines MEMBERS Ponikowski Piotr - Astra Zeneca : acute coronary syndrome ( ) - Boehringer-Ingelheim : anticoagulant, diabetes (2015) - Respicardia : devices (2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2014) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome ( ) - Respicardia : anticoagulant ( ) - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - CIBIEM : heart failure ( ) - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2013) - Singulex : biomarkers (2015) 45/48
46 Committee for Practice Guidelines MEMBERS Roffi Marco - Daiichi Sankyo : antiplatelet therapy (2013) - Lilly : antiplatelet therapy (2013) - Astra Zeneca : antipletelet therapy (2013) - Johnson & Johnson : coronary catheters (2014) - Biosensors : devices ( ) - Boston Scientific : devices ( ) - Medtronic : devices ( ) - Biotronik : devices ( ) - Abbott Vascular : devices ( ) Torbicki Adam - Bristol Myers Squibb : Pulmonary arterial hypertension ( ) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan ( ) - Lilly : pulmonary arterial hypertension - ambrisentan ( ) - Actelion : pulmonary arterial hypertension - macitentan, selexipag ( ) - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto ( ) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015) - Bayer Healthcare : Pulmonary hypertension ( ) Vaz Carneiro Antonio Nothing to be declared (2015) Windecker Stephan - AbbVie : Oncology ( ) - Astra Zeneca : Antiplatelet drug (2013) - Eli Lilly : Antiplatelet drug (2013) 46/48
47 Committee for Practice Guidelines MEMBERS Windecker Stephan - Abbott : Stent (2013) - Medtronic : Stent (2013) - Biotronik : Stent (2013) - Astra Zeneca : Antiplatelet therapy ( ) - Eli Lilly : Antiplatelet therapy ( ) - Bayer Healthcare : Antithrombotic drug ( ) - Abbott : Stent and Heartvalvetherapy ( ) - Biosensors : Stents ( ) - Boston Scientific : Stents ( ) - Medtronic : TAVI, Stent (2015) - Edwards Lifesciences : Transcatheter heart valves (2015) - St Jude Medical : OCT ( ) - Biotronik : Stent ( ) - Medtronic : Stent and Heartvalves (2014) - Medicines Company : Antithrombotic therapy ( ) - Johnson & Johnson : Catheters ( ) - Edwards Lifesciences : Heartvalves ( ) - Abbott : Stent ( ) - Boston Scientific : Stent and Heartvalves ( ) Zamorano Gomez Jose Luis - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) 47/48
48 Committee for Practice Guidelines MEMBERS Zamorano Gomez Jose Luis - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors ( ) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo ( ) - Toshiba medical imaging : Fusion Imaging (2015) C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2013) - Amgen : Clinical trial ( ) - Novartis : Clinical trial ( ) - Ikaria : Clinical trial ( ) 48/48
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan
1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
Pharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct
Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:
PULMONARY HYPERTENSION. This meeting is fully sponsored by GlaxoSmithKline and jointly organised with the Meeting Faculty and GlaxoSmithKline
F O C U S O N PULMONARY HYPERTENSION B O L O G N A 2 0 1 0 1 5 y e a r s o n... p r o g r a m June 24-26, 2010 - Bologna, Italy This meeting is fully sponsored by GlaxoSmithKline and jointly organised
Is There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
Annual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
CHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
The Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
Breakfast symposium: From hospital to home - the focus on the patient
Breakfast symposium: From hospital to home - the focus on the patient Nadya Hamedi DARZI Fellow UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
NOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology
NOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology Department of Medicine Division of Cardiology Nykøbing F Hospital Denmark Disclosure of Conflict of Interest
pulmonary hypertension bologna 2012 Royal Hotel Carlton - Bologna - Italy Under the aegis of alma mater studiorum università di bologna
Under the aegis of alma mater studiorum università di bologna dipartimento cardiovascolare pulmonary hypertension bologna 2012 Royal Hotel Carlton - Bologna - Italy November 23-24, 2012 Friday, november
STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
Corporate Medical Policy
Corporate Medical Policy Pulmonary Hypertension, Drug Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pulmonary_hypertension_drug_management 06/1998 3/2015 3/2016 3/2015
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
Disclosures. Overview. Anticoagulation in 2015: Where We Are and Where We Are Going. Impact of NOACs in Canada
Anticoagulation in 2015: Where We Are and Where We Are Going Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
Introduction. Methods. Study population
New Technologies, Diagnostic Tools and Drugs Schattauer 2012 1 Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world atrial fibrillation
The power of creativity www.originbranding.com. Pharmaceutical Branding 2012
The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered
LEADING-EDGE Cardiovascular Care
LEADING-Edge Cardiovascular Care Coral Gables Hospital North Shore Medical Center Hialeah Hospital Delray Medical Center Good Samaritan Medical Center Palm Beach Gardens Medical Center St. Mary s Medical
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014 Participating Faculty Hector O. Ventura, MD, FACC Section Head, Cardiomyopathy and
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review Review of TA249; Dabigatran etexilate for the prevention of stroke and systemic
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
KEEPING CLINICAL TRIALS IN AUSTRALIA
OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought
Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism
Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism The Swiss Venous Thromboembolism Registry (SWIVTER) Nils Kucher University Hospital
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC87PIDR PUBLICATION DATE FEBRUARY 2015 ATRIAL FIBRILLATION GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below provides the key metrics for atrial fibrillation
ehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
East Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.
rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010
TO: HELENA SALES, POC SPECALISTS, INTERNATIONAL DISTRIBUTORS FROM: HELENA HEMOSTASIS/POINT OF CARE SUBJECT: ROUND-UP DATE: 11/10/2010 General News It has been a while since the last issue but every time
Pulmonary Artery Hypertension
Pulmonary Artery Hypertension Janet M. Pinson, RN, MSN, ACNP Maureen P. Flattery, RN, MS, ANP Virginia Commonwealth University Health System Richmond, VA Pulmonary artery hypertension (PAH) is defined
Guidelines for the Use of Antithrombotic Agents in Cardiac Patients. Stuart J Smith MD Chief of Cardiovascular Services SMGH / GRH
Guidelines for the Use of Antithrombotic Agents in Cardiac Patients Stuart J Smith MD Chief of Cardiovascular Services SMGH / GRH Disclosure of Potential for Conflict of Interest Speaker: Dr Stuart J Smith,
Pharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
Riociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
With unrestricted educational grant from
HOTEL MAKSOUD PLAZA SÃO PAULO SP BRASIL OCTOBER 22-23, 2009 Organization With unrestricted educational grant from As the President of the Brazilian Society of Internal Medicine and the Brazilian Clinical
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia
A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention
CardioSource World News
20 January 2012 OVERWHELMED WITH OPTIONS: The (Mostly) Good News on Novel Oral Anticoagulants in AF I ndustry experts are excited, ready to embrace new oral anticoagulant options. Are you? In recent years,
Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)
A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors
Stroke prevention in AF patients: SOC versus NOAC
Stroke prevention in AF patients: SOC versus NOAC Prof. Dr. Andreas Zirlik Cardio Luxor 2015 Disclosures for Andreas Zirlik, MD In compliance with CME policy, the following disclosures to the session audience
The author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 [email protected] This presentation will discuss unlabeled and investigational use of products The author
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
European Commission Approves EFIENT (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
PERIPHERAL VASCULAR DEVICES
PERIPHERAL VASCULAR DEVICES PRICE: US$3100 NO. OF PAGES: 536 TABLES/CHARTS: 133 REPORT CODE: ARMMR123N.1 PUBLICATION: JUNE 2014 www.axisresearchmind.com Copyright 2014 All Rights Reserved SEGMENTATION
Anticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
Rx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
Commercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
FY2015 Proposed Hospital Inpatient Rule Summary
FY2015 Proposed Hospital Inpatient Rule Summary Cardiac Rhythm Management (CRM) Electrophysiology (EP) Interventional Cardiology (IC) Peripheral Intervention (PI) On April 30, 2014, the Centers for Medicare
Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
Journal of the American College of Cardiology Vol. 61, No. 6, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.057
Cardiovascular Disease: Recent Drug Advances and Impending Risks
Brochure More information from http://www.researchandmarkets.com/reports/2605884/ Cardiovascular Disease: Recent Drug Advances and Impending Risks Description: There are nearly 300 medicines in clinical
Rivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
Como mejorar el manejo médico de los diabéticos con SCA
DIABETES Y ENFERMEDAD CORONARIA EN 2011 Como mejorar el manejo médico de los diabéticos con SCA Antonio Fernández-Ortiz Jueves, 20 Octubre 2011 INSTITUTO CARDIOVASCULAR Conflicto de interés: Antonio Fernández-Ortiz
A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
CLINICAL POLICY Department: Medical Management Document Name: Pulmonary Arterial Hypertension Therapies
Page: 1 of 15 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted